In vitro studies demonstrated that tovorafenib increased ERK phosphorylation at clinically relevant concentrations in cells with neurofibromatosis type 1 loss-of-function (NF–1-LOF), indicating activation rather than inhibition of the MAP kinase pathway. The gene discussed is NF1; the disease is neurofibromatosis type 1.